Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Asterias nets $18.6mm in follow-on offering; reduces Biotime's ownership stake

Executive Summary

Asterias Biotherapeutics Inc. (regenerative medicine cell therapy; subsidiary of BioTime Inc.) netted $18.6mm in a follow-on offering of 5.9mm units (each unit consists of one common share and one-half of one five-year warrant at a $4.37 strike price; includes 742k of over-allotment shares) at $3.40 per unit. The company will put the proceeds toward clinical trials and R&D. Asterias is developing three clinical stage candidates for oncology and neurology. NOTE: After completion of a stock option exercise and the current public offering, BioTime’s ownership in Asterias was reduced from a majority stake to 48.8%.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies